^
    Back
    Association details:
    Biomarker:MBD4 mutation
    Cancer:Uveal Melanoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Eur J Cancer
    Title:

    MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients

    Published date:
    07/18/2022
    Excerpt:
    MBD4 mutation was associated with a better objective response rate as three out of five MBD4m versus 4% of MBD4 wild-type patients responded (p < 0.001)….In mUM patients, MBD4 mutation is highly predictive for the response, PFS, and overall survival benefit to ICI.
    DOI:
    10.1016/j.ejca.2022.06.033